The effect of adjuvant chemotherapy on the prognosis in the patients with familial pancreatic cancer (JON2201-P)

The effect of adjuvant chemotherapy on the prognosis in the patients with familial pancreatic cancer (JON2201-P) - The effect of adjuvant chemotherapy on the prognosis in the patients with familial pancreatic cancer (JON2201-P)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052109

Enrollment

500

Registered

2023-09-06

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer treated with postoperative adjuvant chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent curative resection for primary pancreatic cancer between January 2013 and December 2019 at research collaborate facilities Familial pancreatic cancer patient group: Have a family history of pancreatic cancer in a first-degree relative (parent, sibling, children) Non-familial pancreatic cancer patient group: No family history of pancreatic cancer in first-degree relatives (parents, siblings, children)

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative chemotherapy (neoadjuvant chemotherapy or neoadjuvant chemo-radiotherapy) 2. Patients who have not undergone R0 or R1 resection 3. Histological types other than pancreatic ductal cancer 4. Patients who have not been treated by postoperative adjuvant chemotherapy 5. Patients who have opted out and have been refused access to medical information by research subjects or their familiy

Design outcomes

Primary

Measure	Time frame
Postoperative recurrence-free survival period	—

Countries

Japan

Contacts

Public ContactYuya Miura

Shizuoka Cancer Center Division of Hepato-Biliary-Pancreatic Surgery

yu.miura@scchr.jp055-989-5222

Outcome results